Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
This study will evaluate the pain control and the quality of life of patients with spinal metastases using stereotactic radiotherapy. Stereotactic radiotherapy is referred to as "targeted therapy". It uses special equipment to position the patient and guide the focused beams of radiation toward the cancer and away from normal surrounding tissue. This higher dose technique may work better to kill cancer cells with fewer side effects than standard radiation therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent.
Age greater than or equal to 18 years old.
Prior histologically-proven, non-hematogenous malignancy (Specific exclusions are multiple myeloma and lymphoma).
Radiographic evidence of one or two non-contiguous spinal metastases amenable to SRS.
Metastatic disease must be symptomatic (causing either pain or neurologic symptoms).
Maximum tumor size less than or equal to 5 cm.
Zubrod performance status of less than or equal to 3.
Life expectancy of greater than or equal to 3 months.
Women/Men of childbearing potential must use effective contraception.
You may not be if
No prior radiation delivered to the involved area
No evidence of spinal instability requiring urgent surgical intervention.
No evidence of spinal cord compression requiring emergent surgical or radiotherapeutic intervention.
No plans for concomitant antineoplastic therapy (including standard fractionated RT, chemotherapy, biologic, vaccine therapy, or surgery) while on this protocol except at disease progression.Concomitant is defined as within 3 days before or after radiosurgery.
No pregnant or lactating women.
No active systemic infection.
No evidence of myelopathy or cauda equina syndrome on clinical evaluation
Clareo Health | Stereotactic Radiosurgery (SRS) for Spine Metastases
